A general testing battery for pharmaceuticals includes a bacterial gene mutation assay, an in vitro chromosomal aberration or a gene mutation test on mammalian cells and an in vivo test for chromosome/genome mutations. The aim of this study was to determine whether the in vivo mouse gut micronucleus assay could be a more sensitive method to detect direct clastogens and/or aneugens given orally by gavage than the in vivo bone marrow micronucleus assay (which can also detect indirect genotoxins). Two laboratories collaborated in this project, one analysing bone marrow cells and the other analysing gut cells from the same animals. The reference substances tested in this study were colchicine (COL), carbendazim (CAR), tubulazole (TUB) and griseofulvin (GRI), all known aneugens, and 1,2-dimethylhydrazine (DMH), a colon carcinogen with clastogenic activity. For all substances tested, the in vivo gut micronucleus test was as sensitive as or more sensitive than the in vivo bone marrow micronucleus assay: COL and TUB induced micronuclei in both gut and bone marrow cells; DMH, CAR and GRI induced micronuclei only in gut cells. The results show that the micronucleus test on gut cells is able to detect clastogens and aneugens given orally by gavage, some of which were not detected by the bone marrow micronucleus test.
Introduction
The purposes of genotoxicity testing are (i) to assess the mutagenicity of chemicals, in order to protect the human gene pool and (ii) to identify potential carcinogens. Several more or less specific methodologies are used to detect toxicity towards cells, including protein/DNA coefficient, activity of mitochondrial enzymes, cell proliferation rate, mitotic indices and, more recently, detection of apoptosis or necrosis. Genotoxicity of chemicals in mammalian cells can also be determined in different ways: by identification of DNA damage or adducts, DNA breaks, DNA repair, gene mutations, chromosomal aberrations, chromosome breakage, chromosome loss and non-disjunction. All new chemicals, pharmaceuticals, food and feed additives, packing materials and cosmetics need to undergo a well defined type of (geno-)toxicity screening to fulfil regulatory demands before being placed on the market. The general testing battery for genotoxicity screening of pharmaceuticals consists of a bacterial gene mutation test, an in vitro chromosomal aberration or a gene mutation test on mammalian cells, and an in vivo chromosome/genome mutation test (ICH, 1997) .
In European Union legislation, the only mandatory in vivo test is the rodent bone marrow micronucleus assay. Performing an in vivo test on only one tissue might be misleading, due to the organospecificity of some compounds and the influence of the administration route (intraperitoneal, intravenous or oral) on bioavailibility at the target tissue Ronen and Heddle, 1984; Proudlock and Allen, 1986; Sasaki et al., 1998) . As mentioned by Hayashi et al. (2000) , for unstable compounds or their active metabolites that are too short-lived to reach bone marrow cells, tissues other than bone marrow may be more suitable for assaying clastogenic/ aneugenic effects. It seems logical to consider the epithelium of the gut for in vivo screening of chemicals given orally by gavage since it is the first tissue to come into substantial contact with potentially hazardous chemicals (e.g. food contaminants or pesticides) and since colon cancer is one of the most important forms of cancer in western civilization, both in incidence and lethality.
The aim of this study was to determine whether the in vivo mouse gut micronucleus assay was more sensitive than the bone marrow micronucleus assay at detecting clastogenic and/ or aneugenic activity of chemicals given by oral gavage. Four reference aneugens and one reference clastogen were assessed in an in vivo micronucleus test on bone marrow and gut to determine both genotoxicity (frequency of micronucleated cells in both bone marrow and gut) and toxicity (morphological apoptosis and frequency of mitotic figures in the gut, and proportion of polychromatic erythrocytes (PCEs) versus normochromatic erythrocytes (NCEs) in the bone marrow). The reference substances tested in this study were colchicine (COL), carbendazim (CAR), tubulazole (TUB) and griseofulvin (GRI), all known aneugens, and 1,2-dimethylhydrazine (DMH), a colon carcinogen with clastogenic activity. Two laboratories collaborated in this project, one analysing bone marrow cells and the other analysing gut cells from the same animals.
The colon carcinogen DMH has been widely used to study chemically induced colon cancer. Regardless of the mode of administration, DMH specifically induces tumours within the descending colon; histopathologically these tumours resemble human sporadic colon tumours (Weisburger et al., 1977; Pozharisski et al., 1979; Rogers and Nauss, 1985) . DMH alkylates DNA; the pro-mutagenic lesion O 6 -methylguanine (O 6 -MeG) has also been detected in DNA from rat (Herron and Shrank, 1982) and mouse (Cooper et al., 1978; James and Autrup, 1983) tissues following exposure to DMH. O 6 -MeG is known to induce GC→AT transitions in vitro and in vivo (Loechler et al., 1984; Saffhill et al., 1985) . The induced neoplastic changes in the colon correlate with the persistence of O 6 -MeG (James and Autrup, 1983) , but this methylation does not accumulate when DMH is given in a carcinogenic regimen (Herron and Shank, 1982) . DMH induces a dose-dependent increase in nuclear aberrations in mouse colon (Wargovich et al., 1983) . When given intraperitoneally (20 mg/kg), it induces significant DNA damage (measured with the comet assay) in liver, kidney, brain, bone marrow and mucosa of stomach, colon and bladder, but only in the colon when given orally (20 and 30 mg/kg) (Sasaki et al., 1998) .
COL is an alkaloid product of Colchicum autumnale and worldwide used in medicine to treat gout and other inflammations. It specifically binds to tubulin by interaction with two sites on the α-subunit in tubulin, one with a high affinity and the other with low affinity (Dustin, 1984; Wallin et al., 1988) ; this interaction is only slowly reversible (reviewed by Ö nfelt, 1986) . In this way, COL inhibits tubulin polymerization. It induces aneuploidy in female germ cells (Mailhes et al., 1986) and an increase in hyperploid spermatocytes and male meiotic delay (Adler, 1993; Leopardi, 1993) . Several publications report its potential to induce aneuploidy/polyploidy in somatic mammalian cells of different species (reviewed by Galloway and Ivett, 1986) and in rodent cells in particular (Jenssen and Ramel, 1980; Tsuchimoto, 1980; Yamatoto and Kikuchi, 1981) . COL has been shown to be positive in the bone marrow micronucleus test (Asano et al., 1989; Vanparys et al., 1990; Adler et al., 1991) but more effectively when given intraperitoneally (Asano et al., 1989) . COL induces a statistically significant increase in mitotic index in mouse bone marrow, from a 5 day prolongation of the average cell generation time to complete mitotic arrest (Miller and Adler, 1989; Adler, 1993) .
CAR, a benzimidazole, is a fungicide and the major metabolite of other fungicides like benomyl. It is used worldwide against plant pathogenic fungi, including many Ascomycetes and Basidiomycetes, on many economic crops and in different climates. This compound is hydrolysed in soil and plants to form 2-aminobenzimidazole. In animals, it is metabolized to form (5-hydroxy-1H-benzimidazole-2-yl)-carbamate and other polar metabolites, which are excreted rapidly. Primary exposure of humans is generally due to benomyl and CAR residues in food. High doses of CAR, given by oral gavage to mice and rats, can affect certain microsomal enzymes of the liver (styrene-7,8-hydrolase, epoxide hydrolase and cytolytic glutathione S-transferase). Elaborate studies on several species have demonstrated reproductive, mutagenic and carcinogenic effects associated with the use of benomyl and CAR. CAR is not a gene mutagen, meaning that it does not induce hereditary gene-dependent damage. It does not interact with cellular DNA, induce point mutations or result in germ cell mutations (WHO, 1993) , but others have reported marked cytogenetic effects on germ cells, e.g. the presence of micronuclei, and very early miscarriage when exposure occurred at critical times, coincident with microtubule-dependent meiotic events (Perreault et al., 1992; Zuelke and Perreault, 1995; Jeffay et al., 1996) . CAR gave negative results in the sex-linked recessive lethal test in Drosophila (Lamb and Lilly, 1980) and in assays using induction of chromosome aberrations and sister chromatid exchange in Chinese hamster ovary cells and human lymphocytes in vitro (Lamb and Lilly, 1980; Banduhn and Obe, 1985) . In an in vivo study after intraperitoneal and oral exposure in mice and hamsters, CAR induced micronuclei but no structural chromosomal aberrations in bone marrow cells (Seiler, 1976) . This statistically significant increase of micronuclei in bone marrow cells was also seen by Barale et al. (1993) and Sarrif et al. (1994) . CAR inhibits the polymerization of microtubules in vitro, binding to residue Arg390 in β-tubulin. Elhajouji et al. (1995 Elhajouji et al. ( , 1997 demonstrated that CAR induces chromosome non-disjunction and chromo-40 some loss in a dose-dependent way, and that there is a threshold.
TUB, a synthetic microtubule inhibitor, inhibits polymerization of tubulin in rat brain (ID 50 ϭ 3 ϫ 10 -7 M). It eliminates microtubules in mammalian cells after 30-60 min. Partial dissociation, with loss of cell polarity and mitotic derangement, have also been observed (Van Ginckel et al., 1984; Gevens et al., 1985) . The secondary effects of TUB resemble those of the classical spindle poisons, and include loss of cell polarity, mitotic block and multinucleation (Geuens et al., 1985) . In the mouse bone marrow micronucleus test, TUB was positive at different sampling times (Vanparys et al., 1990; Van Hummelen et al., 1992; Schneider et al., 1995) . In the dominant lethal test in male mice, TUB induced a weak statistically significant increase in early deaths (Vanparys and Marsboom, 1980) . It was not mutagenic in bacteria (Vanparys and Marsboom, 1988) .
GRI, an antibiotic produced by Penicillium griseofulvum, was first isolated in 1938 (Oxford et al., 1939) and acts as a spindle poison (reviewed by DeCarli and Larizza, 1988) . It has been used for many years in the treatment of fungal infections (caused by Microsporum, Trichophyton and Epidermophyton) of skin, nails and hair. Although it does not induce point mutations or DNA repair in bacterial systems, there is a strong synergistic effect with UV-induced mutagenesis (Sideropoulos et al., 1980; DeCarli and Larizza, 1988) . In oocytes, GRI is reported to induce statistically significant dose-dependent increases in cytogenetic abnormalities and hyperploidy depending on the length of exposure of the animals (Marchetti et al., 1992) . In 1992, Marchetti et al. reported that most GRI-induced aneuploid oocytes are fertilized and reach the first cleavage stage, but later Marchetti and Mailhes (1995) reported that GRI decreased the frequency with which fertilized oocytes and one-cell zygotes reached first meiotic metaphase. Aneuploidy, hyperploidy and polyploidy have also been reported, and an upper (500 mg/kg) and a lower (125 mg/kg) threshold for GRI induced aneuploidy in oocytes and one-cell zygotes was found (Marchetti et al., 1996) . In vitro in mouse L5178Y cells (Stopper et al., 1994) and in human peripheral lymphocytes (Migliore et al., 1996) , GRI induces a statistically significant increase in micronuclei, which are mainly centromere positive (Stopper et al., 1994; Migliore et al., 1996) .
Materials and methods

Animals and chemicals
Healthy SPF albino Swiss mice (CD1) (Charles River) were used in this study. During quarantine and the study, the animals had free access to food and tap water. The food was prepared according to an open formula by Janssen Pharmaceutica N.V., with guaranteed analysis and quality control. An air-conditioning system kept the room temperature at 22°C Ϯ 3°C and humidity at 55% Ϯ 20%. The animals were kept in a 12 h light-12 h dark cycle. The mice were 7-9 weeks old at the start of all experiments.
The animals were exposed to a single dose by gavage with a 1 ml tuberculin injection syringe (Becton & Dickinson) . A blunt 4-5 cm hypodermic needle was used as a stomach tube. The dosing volume was 1 ml/kg. Just before dosing, all animals were kept in separate cages, inspected for health and weighed. Only animals weighing 23-43 g were included in the experiments. Two males and two females were used for each point in the preliminary experiment while in the final experiment five males were used (in order to have four scoreable animals). In the final experiment only males were considered, as no qualitative differences in micronucleus induction were found between male and female mice in the preliminary experiment. The animals were killed by cervical dislocation 12, 18, 24, 36, 48 or 72 h after exposure in the preliminary experiment, and 24 or 48 h after exposure in the final experiment.
COL (Aldrich) and DMH (Aldrich) were dissolved in water, while CAR (97%; Aldrich), TUB (R046846; Janssen Research Foundation) and GRI (Sigma) were dissolved in Methocel-Tween (method was purchased from Colorconlimited). All doses used were according to published data. The doses used in the preliminary experiment were 1 and 1.5 mg/kg COL (Vanparys et al., 1990) and 20 and 30 mg/kg DMH (Wargovich et al., 1983; Sasaki et al., 1998) . In an additional dose-finding study, COL was tested at dose levels ranging from 6 to 15 mg/kg (Asano et al., 1989) . In the final experiment, 500 and 1000 mg/kg CAR (WHO, 1994) , 120 and 160 mg/kg TUB (Vanparys et al., 1990) and 1000 and 1500 mg/kg GRI (Marchetti et al., 1992 (Marchetti et al., , 1996 Mailhes et al., 1993; Marchetti and Mailhes, 1995) were administered. The aneugen COL (12 mg/kg) and colon carcinogen DMH (20 mg/kg) were used as positive controls.
In vivo gut micronucleus assay
After cervical dislocation the colon was excised, cut open longitudinally, flushed free of debris with Sörensen buffer (Prosan) and rolled from anus to caecum. These 'Swiss rolls' were fixed in Carnoy fixative (3:1 ethanol:acetic acid), embedded in paraffin (Leica TP 1050, Leica EG 1160), sectioned through the roll (5 µm) (Reichert-Jung Supercut 2050) and stained with Feulgen-Fast Green.
Scoring. Within the structure of the crypts of the colon, the cells were blind scored as normal cells, cells with one or two micronuclei, apoptotic cells or cells with mitotic figures. For each animal, over 1000 epithelial cells were scored (using a whole number of crypts). The total number of cells along the sides of the crypts (both left and right) was recorded. The positions of the endpoints mentioned above were recorded as absolute positions (APs). A relative position (RP) can be calculated from the AP by dividing it by the total number of cells present on that side of the crypt. This RP allows comparison over different crypts and animals, with 0 indicating a position at the bottom of the crypt and 1 a position at the top of the crypt.
A micronucleated epithelial cell was defined as a cell with a normal nucleus and one or two micronuclei, which neither exceeded one-third of the diameter of the main nucleus nor overlapped with it. Cells with a main nucleus and several micronuclei, as well as cells with a fragmented nucleus (apoptotic bodies) were defined as apoptotic cells. Cells with mitotic figures (scored only in the final experiment) were identified as cells in which the chromatin was condensed and visible as chromatids. Normal cells were cells not showing any of these features.
Statistical analysis. Differences in frequency of micronucleated cells, apoptotic cells and mitotic figures between different experimental groups (exposed/ control, different sampling times, different doses) were determined using the Mann-Whitney U-test (two-tailed). To study the position effect (both AP and RP), a Kruskal-Wallis test was performed. The level of significance was set at P ഛ 0.05.
In vivo bone marrow micronucleus assay
After cervical dislocation, one femur per animal was dissected and a small hole was made at the base of the caput. The bone marrow was gently flushed out with fetal calf serum (Gibco). After centrifugation, the bone marrow cells were smeared on to glass slides with a blood smearing instrument (Miniprep, Geometric Data; SmithKline Beecham). The slides were coded for blind analysis. After air drying, the slides were fixed in methanol and stained with Wright stain (Hema Tek Pack) on an automatic apparatus (Hemastainer; SmithKline Beecham). After staining, the slides were automatically mounted (using a Promounter from Medite Meiser) in Shadon (Life Sciences International).
Scoring. For each animal, 1000 PCEs were examined for the presence of micronuclei. The number of micronucleated PCEs (MNPCEs) and micronucleated normochromatic erythrocytes (MNNCEs) observed within the same microscope fields were recorded. The incidence of PCEs per 1000 erythrocytes (PCEs ϩ NCEs) was also determined. For scoring, a Micronucleus Counter JSI 1002 (Janssen Pharmaceutica N.V.) was used.
Statistical analysis. Differences in the incidence per animal of MNPCEs and of PCEs per 1000 erythrocytes (PCEs ϩ NCEs) were compared using the Mann-Whitney U-test (one-tailed). The significance of gender difference was tested with the Mann-Whitney U-test (two-tailed). The level of significance was set at P ഛ 0.01.
Results
Gut micronucleus assay
The results of the mouse in vivo gut micronucleus assay (laboratory 1) are given in Table I for the preliminary experi-41 ment (two doses of COL and DMH) and in Table III Preliminary experiment. The preliminary experiment aimed at defining the adequate sampling time(s) by comparing the effect of an aneugen (COL) and a clastogen (DMH) 12, 18, 24, 36, 48 and 72 h after exposure (Table I, Figure 1 ). Both chemicals increased the frequency of micronucleated cells; in most cases this increase was statistically significant compared with the negative controls (Mann-Whitney U-test; P ഛ 0.05).
For the vehicle control, the frequency of micronucleated cells was very low and stable over the six sampling times. For both doses of DMH, the general trend seen for the frequency of micronucleated cells in the time-course study was more or less the same: after a strong response at the first sampling time (12 h) there was a slight decrease at 18 h (20 and 30 mg/kg) and 24 h (20 mg/kg) followed by an increase. The highest frequency of micronucleated cells in the gut for both doses of DMH was observed 36 h after exposure, after which the frequency of micronucleated cells diminished strongly. However, the incidence of micronucleated cells was still high 48 h after dosing. Both doses of COL gave a fluctuating increase in the frequency of micronucleated cells; no general tendency could be described. Although the 36 h sampling time showed the highest response, we chose to use the 24 and 48 h sampling times for future experiments, since a 36 h sampling time is, in practical terms, more difficult and since the frequency of micronucleated cells was sufficiently increased at 24 and 48 h.
The frequency of apoptotic gut cells was quite variable between animals and sampling times for the vehicle controls. However, a consistent increase in the frequency of apoptotic gut cells was seen for the positive controls (COL and DMH) (Table I, Figure 2 ).
The RP (Table II) of micronucleated and apoptotic gut cells ranged from 0.5 and 0.4 respectively up to 1.0 and increased with sampling time. The upper RP of micronucleated gut cells was reached already after 18 h for the highest dose of COL, after 24 h for the lowest dose of COL and after 48 h for both doses of DMH. For the vehicle controls it was difficult to determine an upper RP for micronucleated cells since only very few micronuclei were present. The upper RP of apoptotic gut cells was already observed 12 h after exposure for both doses of COL, and 48 h after exposure for the lowest dose of DMH. In the vehicle controls an RP of 1 was also observed at the 72 h sampling time.
Correlation coefficients between frequencies of micronucleated gut cells and apoptotic gut cells were low (r 2 ranging from 0.0012 to 0.1829) for the preliminary experiment. Only for DMH was statistically significant correlation (r 2 value) at a 5% level observed.
Final experiment. For the vehicle controls (water and Methocel-Tween), the incidence of micronucleated cells was comparable to that found in the preliminary study (Table IIIa  and Figure 3 ). Both positive controls (12 mg/kg COL and 20 mg/kg DMH) showed a statistically significant increase in the frequency of micronucleated gut cells. This statistically significant increase in the frequency of micronucleated gut cells was also observed at one or both sampling times for the test substances CAR, TUB and GRI. Thus, all the aneugens at all doses tested scored positive but a dose-response relationship was not observed. Usually (except for GRI) the lower dose had a (little) higher effect than the higher doses.
Only the positive controls COL and DMH and the aneugen TUB induced a statistically significant increase in apoptotic gut cells (Table IIIa and Figure 4) . COL induced a statistically significant increase in the frequency of mitotic figures, and DMH induced a statistically significant decrease in the frequency of mitotic figures (Table  IIIb and Figure 5 ). The test substances TUB, CAR, and GRI all induced only a slight increase (with no statistical significance) in the frequency of mitotic figures.
As far as the RP of micronucleated and apoptotic gut cells was concerned, 20 mg/kg DMH showed effects comparable to those in the preliminary experiment (Table II) . The highest RP for micronuclei, apoptotic cells and mitotic figures ranged for all compounds from 0.6 to 1.0, 0.4 to 1.0 and 0.4 to 0.85, respectively. Again, the highest RP of micronucleated cells and apoptotic cells was reached at later sampling times. As far as mitotic figures are concerned, the highest RP never reached 1.0; when the highest RP of mitotic figures were compared between aneugens, clastogens and negative controls, the mitotic figures in animals treated with aneugens could be found higher up in the crypts than in the animals treated with DMH or in the vehicle control animals.
In the final experiment, correlation coefficients between frequencies of micronucleated gut cells and apoptotic gut cells were also low (r 2 ranging from 0.0213 to 0.8851). Significant correlations were found neither between micronucleated gut cells and gut cells with mitotic figures (r 2 ranging from 0.0005 to 0.1881) nor between apoptotic gut cells and gut cells with mitotic figures (r 2 ranging from 0.0023 to 0.1761). Only for TUB was a statistically significant correlation (r 2 ) at the 5% level found. In each set of individual data, the first two results are from females and the last two from males. *P ഛ 0.05. Abbreviations: SD, standard deviation; VC, vehicle control. 
Bone marrow micronucleus test
The results of the bone marrow micronucleus tests are shown in Tables IV to VI. The mean frequency of MNPCEs per treatment point and the individual number of MNPCEs and number of PCEs per 1000 (PCEs ϩ NCEs) are shown. As the number of MNNCEs did not give further information, the incidence of MNNCEs is not detailed in the tables.
Preliminary experiment. The first experiment was carried out with 20 and 30 mg/kg DMH and 1 and 1.5 mg/kg COL administered once, orally by gavage. The animals were killed at the same sampling times as for the in vivo gut micronucleus test. The individual incidence of MNPCEs in male and female mice of the vehicle control group (water) was within our laboratory negative control range of 0-4 MNPCEs/1000 PCEs (Table IV) . No statistically significant increase in the number of MNPCEs over the vehicle control value was obtained at any sampling time with mice given either 20 and 30 mg/kg DMH or 1 and 1.5 mg/kg COL. In mice given 30 mg/kg DMH, a small but not statistically significant (P ϭ 0.08) increase in MNPCEs was observed at the 36 h sampling time.
Since the increase was related to only one male mouse and all the other mice showed a micronucleus incidence comparable to that in the vehicle control and the historical control range of 0-4 MNPCEs/1000 PCEs, this increase was considered to be a fortuitous one. Furthermore, none of the animals at the other sampling times showed any increase in the number of MNPCEs. COL and DMH at the used dose levels did not induce a decrease in bone marrow proliferation.
As the model aneugen COL did not increase the frequency 1.8 Ϯ 1.2 9/5000 (1,3,2,0,3) 53.9 Ϯ 6.5
All data from males. Abbreviations as in Table IV . *P ഛ 0.01.
of MNPCEs in bone marrow cells, an additional study using higher doses of COL was set up. Male and female mice were dosed once orally with COL at 6, 9, 12 and 15 mg/kg bodyweight and bone marrow was sampled 24 h after dosing. At all doses, COL induced an increase in the number of MNPCEs in bone marrow (Table V) . The increase was statistically significant only in the groups given 6 and 15 mg/kg bodyweight. At 12 and 15 mg/kg COL, a statistically significant (P ഛ 0.05) decrease in the proportion of PCEs was noted, proving bone marrow exposure.
Final experiment. In the final experiment, the vehicle control animals showed a normal micronucleus incidence (0-4 MNPCEs/1000 PCEs) (Table VI) . At both sampling times, the positive control COL, at a dose of 12 mg/kg, induced a statistically significant increase (P ഛ 0.01) in the number of MNPCEs. The micronucleus-inducing potential of COL was more pronounced in this study than in the preceding study at the same dose. At both sampling times COL also induced a statistically significant (P ഛ 0.01) decrease in bone marrow proliferation. Since the vehicle and positive control induced an acceptable level of effect, this study was accepted for the evaluation of clastogenic and aneugenic potential of the test compounds. The positive control DMH, which is positive in the gut micronucleus test, did not increase the bone marrow micronucleus frequency or decrease bone marrow proliferation, as was found in the first study. TUB at 120 and 160 mg/kg induced a statistically significant (P ഛ 0.01) increase in MNPCEs and statistically significant (P ഛ 0.01) decrease in bone marrow proliferation at both sampling times. CAR at 500 and 1000 mg/kg and GRI at 1000 and 1500 mg/kg did not induce a statistically significant increase in MNPCEs at any of the sampling times.
Discussion
Gut micronucleus test
This in vivo study compared the frequencies of micronucleated cells, the RP of micronucleated cells and the frequencies and
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RPs of apoptotic cells and cells with mitotic figures after exposure to one clastogen (DMH) and several aneugens (COL, CAR, TUB and GRI). All doses of the clastogen and the aneugens tested affected the frequency of micronucleated cells at one or more sampling times in the gut micronucleus test. The gut micronucleus test can thus detect both aneugenic and clastogenic activity of chemicals.
The fact that no dose-response relationship was observed for aneugens and that, for similarly acting spindle poisons (Elhajouji et al., 1995 (Elhajouji et al., , 1997 , a threshold concentration has been proposed on the basis of in vitro tests in human lymphocytes, suggests that a threshold for induction of micronucleated cells is highly probable also in the in vivo mouse gut micronucleus assay. Additional studies with more compounds and more adequately spaced doses are required before drawing conclusions.
To interpret the RP of micronucleated cells, it is essential to consider the particular cell kinetics of epithelial gut cells. In the large intestine, the stem cells, which divide slowly, are located at the bottom of the crypt. The progeny of the stem cells either remain stem cells or enter a transient proliferating cell population that differentiates to produce the functional cells of the tissue; they are located in that part of the crypt closest to the lumen. The transit cells are located between the stem cells and the functional cells (Heddle et al., 1996) . In this system, the cells migrate up to the lumen of the gut (in 3-5 days) where they are exfoliated into the lumen.
The upper limits observed for the endpoints are given in Table II (raw data not shown). In the preliminary experiment the trends observed for the RP of micronucleated cells and apoptotic cells confirm the kinetics of the system: with time, both micronucleated cells and apoptotic cells either remain at the bottom of the crypt or migrate to the upper part of the crypt. These migrating cells are pushed to higher parts of the crypt by division of the stem and transit cells. In the final experiment, the same trends were seen. The decrease in total frequency of micronucleated cells can be explained by a balance between cell death by apoptosis or necrosis (occurring between sampling times) and cell survival. The accuracy of the criteria used by us to identify apoptotic cells [cells with a main nucleus and several micronuclei, as well as cells with a fragmented nucleus (apoptotic bodies) were defined as apoptotic cells] can be questioned because of the large variation of the frequencies of apoptotic gut cells at the different sampling times for the vehicle control; perhaps cells with more than two micronuclei should have been included in the category of micronucleated cells rather than in the category of apoptotic cells. We suggest that it might be better to use an early event of apoptosis, e.g. exposure of phosphatidylserine on the outer membrane of the cells, that can easily be detected using annexin-V staining when single cells in suspension are available, instead of using a late event of apoptosis like the fragmentation of the nucleus. Either way, apoptosis is not the only way of eliminating cells. Necrosis is also a possibility but was not scored in this study. In future experiments, it would be advisable to use the guidelines for scoring necrotic and apoptotic cells according to Fenech et al. (1999) .
Mitotic figures should only be seen in the population of cells that can divide, i.e. the lower parts of the crypts containing the cells of the proliferative and stem cell compartments. This was indeed observed in the crypts in the clastogen-exposed animals and the vehicle control animals (RP of 0.55 and 0.60). However, these mitotic figures were found higher in the crypts in the aneugen-exposed animals, which indicates a block in cell division, with mitotic figures that 'survive' (cells that are blocked in mitosis, and do not complete the cell cycle) and migrate upwards in the crypts.
Statistically significant correlations between frequencies of micronucleated gut cells, apoptotic gut cells and gut cells with mitotic figures were not found and no conclusion on the survival of micronuclei could be drawn. Again, our criteria for defining apoptotic cells must be questioned, because a decrease in the frequency of micronucleated cells was expected to be compensated by an increase in the frequency of apoptotic cells, although apoptosis is a process that could be completed in the interval between two sampling times.
Bone marrow micronucleus test
Single oral administration of DMH (gavage) to mice did not increase the number of MNPCEs in mouse bone marrow at any of the sampling times (12, 18, 24, 36, 48 and 72 h) . Comparable findings have been reported by Goldberg et al. (1983) , who treated mice once intraperitoneally with 15 mg/kg DMH and sampled bone marrow 24, 48 and 72 h later, while a strong increase in micronucleated colonic epithelial cells was found 24 h after dosing. DMH has also been reported to be negative in the bone marrow micronucleus test by Trzos et al. (1978) . In the final experiment, we did not test a higher dose of DMH in order to obtain positive results in the bone marrow (as was done for COL), since we felt that the doses used were sufficiently high, and that the negative results in the bone marrow were due to the tissue specificity of DMH.
COL at ജ6 mg/kg administered once orally induced a statistically significant increase in MNPCEs. At the lower doses, 1 and 1.5 mg/kg [which have been shown to effective when given intraperitoneally (Asano et al., 1989; Van Hummelen et al., 1992) ], no statistically significant increase in MNPCEs was observed. Asano et al. (1989) also found that the first important increase in MNPCEs occurred at a dose 8 mg/kg COL when given orally to MS/Ae and CD-1 mice.
In this study CAR at 500 and 1000 mg/kg did not induce micronucleus formation in the bone marrow micronucleus assay. This contrasts with the findings of others (Pandita, 1988; Barale et al., 1993; Sarrif et al., 1994) , who observed micronucleus induction in bone marrow after exposure to CAR. Pandita (1988) gave two doses of CAR intraperitoneally (given 24 h apart) (total doses 200, 1000, 2000, 4000 and 6000 mg/kg CAR), sampled bone marrow 6 h after the second dosing and found a statistically significant increase in the frequency of MNPCEs with the three highest doses used. Sarrif et al. (1994) gave mice a single oral dose of 66, 1646 and 3293 mg/kg CAR and sampled 48 h after exposure. The two highest doses induced a statistically significant increase in (mainly kinetochore containing) micronuclei. In both studies micronuclei were induced at higher doses than the ones used in this study. Barale et al. (1993) found a quite small increase in frequency of MNPCEs after a single oral dose of 500 mg/kg CAR (a dose at which we did not find statistically significant induction of micronuclei in the bone marrow) which was highest 36 h after exposure (1.68 Ϯ 1.05 MNPCEs/1000 bone marrow cells for the controls, 3.76 Ϯ 0.28 for CAR at 24 h and 3.49 Ϯ 0.43 for CAR at 48 h (where we had 4.2 Ϯ 2.4 and 1.0 Ϯ 0.9 MNPCEs/1000 bone marrow cells after 24 and 48 h, respectively, compared with 0.8 Ϯ 0.8 and 0.4 Ϯ 0.5 at 24 and 48 h, respectively, after exposure to the vehicle control) and 6.40 Ϯ 2.36 at 36 h and 5.66 Ϯ 2.41 at 42 h after exposure. Maybe the difference in vehicles used by respectively) could be responsible for the discrepancies between the different micronucleus assay results. TUB at 160 mg/kg induced a strong increase in MNPCEs at both sampling times as reported earlier with oral administration (Vanparys et al., 1990 . Table VII shows the comparison of the in vivo bone marrow and the in vivo gut micronucleus test for the clastogen DMH and the aneugens COL, CAR, TUB and GRI. The three orally administered compounds that were negative in the bone marrow micronucleus test (DMH, CAR and GRI) did not reduce bone marrow proliferation, so that sufficient bone marrow exposure must be questioned. However, other authors reported effects in germ cells at lower doses than the maximum doses used in this study. For DMH and TUB no germ cell data were available to us, but CAR given at 1000 mg/kg (the higher dose tested in this study) by gavage is known to induce numerical aberrations, abnormal zygote formation and early pregnancy loss (Jeffay et al., 1996) and decreased embryo development to the two-cell stage (Zuelke and Perreault, 1995) in mice, while doses of 250-1000 mg/kg in hamsters reduced the percentage of pregnant hamsters and the number of live pups (Perreault et al., 1992) . COL at 1, 2 3 and 6 mg/kg significantly increases the hyperploidy index in mouse secondary spermatocytes (Leopardi et al., 1993) and GRI at 1500 mg/kg reduces the frequency of fertilized oocytes and induces hyperdiploidy and aneuploidy in oocytes of superovulated mice (Marchetti and Mailhes, 1995) . Therefore, one cannot exclude the possibility that the lack of increase in micronuclei in bone marrow cells in our experiments was caused by lack of bioavailability, relative concentration differences or difference in absorption in the gut and bone marrow. Pharmacokinetic data could provide an answer to these important questions, but no such data were available to us.
Comparison between bone marrow and gut micronucleus test
The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use clearly recommend the demonstration of target exposure in the case of negative findings for in vivo bone marrow cytogenetic assays (ICH, 1995) . In the absence of proof of bone marrow exposure, visualized by a decrease in PCE/NCE ratio, or of relevant toxicokinetic data, another tissue should be considered. On the basis of the results obtained with this study, the gut micronucleus test may be a good alternative to the bone marrow micronucleus test. Such a test might be more appropriate for compounds intended to be given orally, since cells of the gastrointestinal tract would be the first to come in contact with compounds given by this route. All the compounds tested in this study were indeed positive in the gut micronucleus test. Interestingly, the colon carcinogen DMH, which was negative in the bone marrow micronucleus test, elicited a strong clastogenic/aneugenic response in the gut micronucleus test. In this respect, sensitivity of the gut micronucleus test for the detection of colon carcinogens should be further explored.
In conclusion, the results presented in this paper show that the micronucleus test on gut cells is able to detect clastogens and aneugens, some of which do not show activity in the bone marrow micronucleus test after oral exposure.
